Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Ionis Pharmaceuticals (IONS) has been drawing attention after recent price moves, with shares last closing at US$73.27. Investors are weighing this level against the company’s fundamentals, recent returns and pipeline-driven revenue profile.
See our latest analysis for Ionis Pharmaceuticals.
The recent pullback, with a 1-day share price return of a 1.11% decline at US$73.27, comes after a 1-year total shareholder return of 146.70%. This suggests some investors may be reassessing near term risks while the longer term story remains intact.
If Ionis’s biotech profile has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 33 healthcare AI stocks
With Ionis posting a 1 year total return above 140%, double digit annual revenue growth and an analyst price target implying room above US$73.27, you have to ask: is there still upside here, or is the market already baking in future growth?
Ionis Pharmaceuticals latest close at $73.27 sits well below the most followed fair value estimate of $96.73, framing a valuation story built around aggressive growth and margin assumptions that investors will want to scrutinize.
The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.
Want to see what kind of revenue curve and margin shift are baked into that fair value? The narrative leans on ambitious growth, improving profitability, and a rich future earnings multiple that are all tied to a tight set of forecast assumptions.
Result: Fair Value of $96.73 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there is still meaningful risk if key late stage approvals slip, or if pricing and reimbursement pushbacks squeeze margins and delay the profit inflection story.
